The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Robbins Wendye since 2019.
This trader's CIK number is 1791244.
At the time of last reporting, Robbins Wendye was the Director of Rapt Therapeutics, Inc.. (stock ticker symbol RAPT).
Also see all insider trading activities at Rapt Therapeutics, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2023 | RAPT | 5,000 | $96,540 | 0 | $0 | 0 | $0 |
| 2022 | RAPT | 7,000 | $76,139 | 0 | $0 | 0 | $0 |
| 2021 | RAPT | 6,600 | $180,807 | 0 | $0 | 0 | $0 |
| 2020 | RAPT | 5,600 | $135,623 | 0 | $0 | 0 | $0 |
| 2019 | RAPT | 1,600 | $19,200 | 0 | $0 | 0 | $0 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2023-03-14 | RAPT | Buy | 5,000 | 19.31 | 96,540 |
| 2022-05-10 | RAPT | Buy | 7,000 | 10.88 | 76,139 |
| 2021-10-18 | RAPT | Buy | 500 | 30.70 | 15,350 |
| 2021-10-13 | RAPT | Buy | 400 | 29.69 | 11,876 |
| 2021-08-23 | RAPT | Buy | 1,475 | 31.42 | 46,338 |
| 2021-08-24 | RAPT | Buy | 525 | 30.91 | 16,225 |
| 2021-08-20 | RAPT | Buy | 600 | 29.64 | 17,785 |
| 2021-07-07 | RAPT | Buy | 1,000 | 30.18 | 30,175 |
| 2021-04-13 | RAPT | Buy | 700 | 19.45 | 13,615 |
| 2021-04-09 | RAPT | Buy | 1,400 | 21.03 | 29,443 |
| 2020-11-19 | RAPT | Buy | 1,000 | 16.09 | 16,085 |
| 2020-09-28 | RAPT | Buy | 500 | 28.68 | 14,337 |
| 2020-09-23 | RAPT | Buy | 400 | 29.30 | 11,719 |
| 2020-09-24 | RAPT | Buy | 200 | 28.00 | 5,600 |
| 2020-07-24 | RAPT | Buy | 900 | 22.50 | 20,250 |
| 2020-07-01 | RAPT | Buy | 1,000 | 26.40 | 26,400 |
| 2020-06-29 | RAPT | Buy | 1,600 | 25.77 | 41,232 |
| 2019-11-04 | RAPT | Buy | 1,600 | 12.00 | 19,200 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Robbins Wendye (Director of Rapt Therapeutics, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.